The Massachusetts–based startup will use the funds to support the development of its oral small molecule drugs it claims have neurorestorative properties, including a GPR17 antagonist that could promote the remyelination of neurons, as well as a CSF1R inhibitor that could target the demyelination process and neuroinflammation.